5+ years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
See more jobs for students and recent grads who studied:
Real World Evidence Manager
Biogen | Weston, Massachusetts
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleReal World Evidence Manager
Job DescriptionThe main responsibility of this person would be to provide execution, expertise, direction and input in strategy for Real World Evidence (RWE) generation in the US to further enhance the medical value of Biogen products and therapeutic areas for the MVLs and MSLs to be used with Payers and Providers, respectively. This person will proactively monitor and analyze the state of the art in RWE generation and health outcomes research/CER on a continued basis to guide strategic and tactical oversight within US Medical by using innovative, scientifically robust approaches to phase IV and Life Cycle Management products as well as utilize RWE generation to inform Biogen' s clinical trial programs. This role will serve as the US Medical and US Market Access & Reimbursement (MA&R) primary contact and lead for scientific research collaborations with US External Stakeholders (Payers, Providers, Advocacy and Policy) and will have the responsibility of understanding the changing healthcare landscape and how the RI2 will need to implement innovative approaches in generating value based medical outcomes.
Role and Responsibilities
Designs and implements innovative, scientifically robust health economics and outcome studies through use of internal databases and analytics team, managing external vendors, and/or research collaborations with Providers or Payers, primarily to support the value proposition for phase IV products in an evolving US healthcare system
Deliver on innovation and customer centric service through identification and delivery of innovative opportunities for building the medical value of in-market (new indication/indication expansion) and pipeline products
Collaborate cross-functionally with US and Global Biogen stakeholders (e.g., Medical, Commercial, and Market Access teams) to identify onging evidence requirements in the context of the evolving healthcare landscape
Become an integral member of the Real World Data LCMF team focused on health outcome, pharmacoeconomic and CER study proposals to critically evaluate the design, endpoints and scientific merit of proposed research.
Collaborate with the Global Market Access team to provide medical input into the development of BIM, CE models and retrospective claims analysis
Collaborate with MA&R, Medical Directors, Worldwide Medical, and Marketing teams to provide medical input into the development of key initiatives, resources, tools, and training.
LocationWeston, MA, US
Job CategoryGlobal Medical/Medical Affairs
Requisition Number30987BR
QualificationsExtensive knowledge and experience with Managed Markets (5+ years) and/or in the biotech/pharmaceutical industry.
Demonstrated ability to work in a matrix reporting structure (3+ years).
Knowledge of clinical trials, epidemiology, registries, drug development and outcomes research (HEOR and CER). Thorough understanding of research methods, health outcomes research and pharmacoeconomic evaluations and related disciplines.
Strong project management skills. Demonstrated ability to effectively communicate within a large organization
Excellent interpersonal, communication and management capabilities
Independent and able to solve complex and challenging problems using innovative strategies
EducationAdvanced scientific/medical training equivalent to PhD (in health services research, health economics or relevant life sciences discipline), MD, or Pharm.D required.
About BiogenCorporate Overview
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.
  • Biogen was founded in 1978 and today serves patients in nearly 70 countries.
  • A Fortune 500 company, Biogen in 2016 had revenues of $11.4 billion
  • Global headquarters in Cambridge, MA, and international headquarters in Zug, Switzerland
Our Science
We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.
  • For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease.
  • We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS.
  • As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.
  • Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.
Our Corporate Citizenship
The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.